Publication: Southeast Asian Pharmacogenomics Research Network (SEAPharm): Current Status and Perspectives
Issued Date
2019-12-01
Resource Type
ISSN
16628063
16624246
16624246
Other identifier(s)
2-s2.0-85073694205
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Public Health Genomics. Vol.22, No.3-4 (2019), 132-139
Suggested Citation
Supatat Chumnumwat, Zen Huat Lu, Chonlaphat Sukasem, Michael David Winther, Francis R. Capule, Asma A.tiyah Abdul Hamid, Bibek Bhandari, Usa Chaikledkaew, Noppadol Chanhom, Soranun Chantarangsu, Angkana Charoenyingwattana, Tong Thi Hang, Tin Maung Hlaing, Kyaw Soe Htun, Jiraphun Jittikoon, Ly Le, Surakameth Mahasirimongkol, Dzul Azri Mohamed Noor, Jesus Shrestha, Lakkana Suwannoi, Pramote Tragulpiankit, Saowalak Turongkaravee, Sukanya Wattanapokayakit, Phonepadith Xangsayarath, Rika Yuliwulandari, Shamsul Mohd Zain, Wasun Chantratita Southeast Asian Pharmacogenomics Research Network (SEAPharm): Current Status and Perspectives. Public Health Genomics. Vol.22, No.3-4 (2019), 132-139. doi:10.1159/000502916 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/51294
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Southeast Asian Pharmacogenomics Research Network (SEAPharm): Current Status and Perspectives
Author(s)
Supatat Chumnumwat
Zen Huat Lu
Chonlaphat Sukasem
Michael David Winther
Francis R. Capule
Asma A.tiyah Abdul Hamid
Bibek Bhandari
Usa Chaikledkaew
Noppadol Chanhom
Soranun Chantarangsu
Angkana Charoenyingwattana
Tong Thi Hang
Tin Maung Hlaing
Kyaw Soe Htun
Jiraphun Jittikoon
Ly Le
Surakameth Mahasirimongkol
Dzul Azri Mohamed Noor
Jesus Shrestha
Lakkana Suwannoi
Pramote Tragulpiankit
Saowalak Turongkaravee
Sukanya Wattanapokayakit
Phonepadith Xangsayarath
Rika Yuliwulandari
Shamsul Mohd Zain
Wasun Chantratita
Zen Huat Lu
Chonlaphat Sukasem
Michael David Winther
Francis R. Capule
Asma A.tiyah Abdul Hamid
Bibek Bhandari
Usa Chaikledkaew
Noppadol Chanhom
Soranun Chantarangsu
Angkana Charoenyingwattana
Tong Thi Hang
Tin Maung Hlaing
Kyaw Soe Htun
Jiraphun Jittikoon
Ly Le
Surakameth Mahasirimongkol
Dzul Azri Mohamed Noor
Jesus Shrestha
Lakkana Suwannoi
Pramote Tragulpiankit
Saowalak Turongkaravee
Sukanya Wattanapokayakit
Phonepadith Xangsayarath
Rika Yuliwulandari
Shamsul Mohd Zain
Wasun Chantratita
Other Contributor(s)
YARSI University
International University,Vietnam National University Ho Chi Minh City
UNIVERSITI BRUNEI DARUSSALAM
Kathmandu Medical College
University of the Philippines Manila
A-Star, Genome Institute of Singapore
University of Malaya
Chulalongkorn University
National University of Singapore
Faculty of Medicine, Ramathibodi Hospital, Mahidol University
Thailand Ministry of Public Health
Mahidol University
Universiti Sains Malaysia
Vingroup Big Data Institute
Defence Services Medical Research Centre (DSMRC)
National Center for Laboratory and Epidemiology
Ministry of Health
International University,Vietnam National University Ho Chi Minh City
UNIVERSITI BRUNEI DARUSSALAM
Kathmandu Medical College
University of the Philippines Manila
A-Star, Genome Institute of Singapore
University of Malaya
Chulalongkorn University
National University of Singapore
Faculty of Medicine, Ramathibodi Hospital, Mahidol University
Thailand Ministry of Public Health
Mahidol University
Universiti Sains Malaysia
Vingroup Big Data Institute
Defence Services Medical Research Centre (DSMRC)
National Center for Laboratory and Epidemiology
Ministry of Health
Abstract
© 2019 S. Karger AG, Basel. Copyright: All rights reserved. Pharmacogenomics (PGx) is increasingly being recognized as a potential tool for improving the efficacy and safety of drug therapy. Therefore, several efforts have been undertaken globally to facilitate the implementation process of PGx into routine clinical practice. Part of these efforts include the formation of PGx working groups working on PGx research, synthesis, and dissemination of PGx data and creation of PGx implementation strategies. In Asia, the Southeast Asian Pharmacogenomics Research Network (SEAPharm) is established to enable and strengthen PGx research among the various PGx communities within but not limited to countries in SEA; with the ultimate goal to support PGx implementation in the region. From the perspective of SEAPharm member countries, there are several key elements essential for PGx implementation at the national level. They include pharmacovigilance database, PGx research, health economics research, dedicated laboratory to support PGx testing for both research and clinical use, structured PGx education, and supportive national health policy. The status of these essential elements is presented here to provide a broad picture of the readiness for PGx implementation among the SEAPharm member countries, and to strengthen the PGx research network and practice in this region.